<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Sinovac Biotech Publishes Mixed Clinical Trial Results
Image Overlay - Sinovac Biotech Publishes Mixed Clinical Trial Results

Sinovac Biotech Publishes Mixed Clinical Trial Results

Sinovac Biotech Publishes Mixed Clinical Trial Results

Chinese-based Sinovac Biotech has released mixed findings from its two first clinical trials for a COVID-19 vaccine. Though the early clinical trials indicate that the vaccine is well-tolerated, the company has reported that it generates lower levels of protective antibodies in the bloodstream, compared with levels found in patients who have recovered from the coronavirus. Sinovac believes its vaccine will still be effective despite the lower antibody levels, and phase III trials are currently being conducted in Indonesia, Brazil, and Turkey. Yourway has 21 strategically located global depots worldwide, including São Paulo, Tel Aviv, and Singapore, to ensure that clinical trial supplies are transported smoothly from one location to another — no matter where trials take place.

Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Global Clinical Supplies Group (GCSG)

October 14-16, 2025
Hungary, Budapest

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Media

Articles

Critical Packaging and Labeling Considerations for Decentralized Clinical Trials

Open chat
Come chat with us!
Hello! How can I help you?